NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis
Humira biosimilars set to launch in EU next month
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
Thync’s bioelectronic wearable significantly reduced symptoms in psoriasis patients within four weeks of use.
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.